122 related articles for article (PubMed ID: 35121918)
1. Targeting BRCA-mutated tumors in mitosis.
Menolfi D; Zha S
Nat Cancer; 2021 Dec; 2(12):1296-1297. PubMed ID: 35121918
[No Abstract] [Full Text] [Related]
2. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
[TBL] [Abstract][Full Text] [Related]
3. Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Dworkin AM; Spearman AD; Tseng SY; Sweet K; Toland AE
Fam Cancer; 2009; 8(4):339-46. PubMed ID: 19340607
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.
Yip CH; Taib NA; Choo WY; Rampal S; Thong MK; Teo SH
World J Surg; 2009 Oct; 33(10):2077-81. PubMed ID: 19649760
[TBL] [Abstract][Full Text] [Related]
5. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Ghouadni A; Delaloge S; Lardelli P; Kahatt C; Byrski T; Blum JL; Gonçalves A; Campone M; Nieto A; Alfaro V; Cullell-Young M; Lubinski J
Breast; 2017 Aug; 34():18-23. PubMed ID: 28467918
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical Evaluation of BAP1 Expression in Breast Cancer with Known
Çalım-Gürbüz B; Güvendir İ; Ünal B; Erdoğan-Durmuş Ş; Topal CS; Ağaoğlu NB; Doğanay HL; Kızılboğa T; Zemheri IE
Int J Surg Pathol; 2022 Jun; 30(4):397-404. PubMed ID: 35261270
[No Abstract] [Full Text] [Related]
7. Androgen pathway dysregulation in BRCA1-mutated breast tumors.
Berns EM; Dirkzwager-Kiel MJ; Kuenen-Boumeester V; Timmermans M; Verhoog LC; van den Ouweland AM; Meijer-Heijboer H; Klijn JG; van der Kwast TH
Breast Cancer Res Treat; 2003 May; 79(1):121-7. PubMed ID: 12779088
[TBL] [Abstract][Full Text] [Related]
8. BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.
Mohanty SK; Lai JP; Gordon OK; Pradhan D; Bose S; Dadmanesh F
Breast J; 2015; 21(6):596-603. PubMed ID: 26390986
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Hennessy BT; Timms KM; Carey MS; Gutin A; Meyer LA; Flake DD; Abkevich V; Potter J; Pruss D; Glenn P; Li Y; Li J; Gonzalez-Angulo AM; McCune KS; Markman M; Broaddus RR; Lanchbury JS; Lu KH; Mills GB
J Clin Oncol; 2010 Aug; 28(22):3570-6. PubMed ID: 20606085
[TBL] [Abstract][Full Text] [Related]
10. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
[TBL] [Abstract][Full Text] [Related]
11. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
[TBL] [Abstract][Full Text] [Related]
12. [Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy].
Levanat S; Cvok ML
Lijec Vjesn; 2010; 132(1-2):34-7. PubMed ID: 20359158
[TBL] [Abstract][Full Text] [Related]
13. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
14. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
Cline MS; Liao RG; Parsons MT; Paten B; Alquaddoomi F; Antoniou A; Baxter S; Brody L; Cook-Deegan R; Coffin A; Couch FJ; Craft B; Currie R; Dlott CC; Dolman L; den Dunnen JT; Dyke SOM; Domchek SM; Easton D; Fischmann Z; Foulkes WD; Garber J; Goldgar D; Goldman MJ; Goodhand P; Harrison S; Haussler D; Kato K; Knoppers B; Markello C; Nussbaum R; Offit K; Plon SE; Rashbass J; Rehm HL; Robson M; Rubinstein WS; Stoppa-Lyonnet D; Tavtigian S; Thorogood A; Zhang C; Zimmermann M; ; Burn J; Chanock S; Rätsch G; Spurdle AB
PLoS Genet; 2018 Dec; 14(12):e1007752. PubMed ID: 30586411
[TBL] [Abstract][Full Text] [Related]
15. Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
Ha SM; Chae EY; Cha JH; Kim HH; Shin HJ; Choi WJ
AJR Am J Roentgenol; 2017 Oct; 209(4):920-928. PubMed ID: 28796549
[TBL] [Abstract][Full Text] [Related]
16. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
17. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
[TBL] [Abstract][Full Text] [Related]
18. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
19. Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer.
McCabe N; Cerone MA; Ohishi T; Seimiya H; Lord CJ; Ashworth A
Oncogene; 2009 Mar; 28(11):1465-70. PubMed ID: 19182824
[TBL] [Abstract][Full Text] [Related]
20. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
